Search hospitals
>
Missouri
>
Saint Louis
Barnes Jewish Hospital
Claim this profile
Saint Louis, Missouri 63110
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Lymphoma
Conducts research for Heart Failure
Conducts research for Leukemia
384 reported clinical trials
35 medical researchers
Summary
Barnes Jewish Hospital is a medical facility located in Saint Louis, Missouri. This center is recognized for care of Lung Cancer, Breast Cancer, Lymphoma, Heart Failure, Leukemia and other specialties. Barnes Jewish Hospital is involved with conducting 384 clinical trials across 607 conditions. There are 35 research doctors associated with this hospital, such as Yan Wang, David G Mutch, M.D., Ramzi Abboud, M.D., and Puja Kachroo, MD.
Area of expertise
Lung Cancer
Barnes Jewish Hospital has run 33 trials for Lung Cancer. Some of their research focus areas include:
Breast Cancer
Barnes Jewish Hospital has run 20 trials for Breast Cancer. Some of their research focus areas include:
Top PIs
Yan Wang
Xiamen Cardiovascular Hospital Xiamen University
6 years of reported clinical research
David G Mutch, M.D.
Washington University School of Medicine
1 year of reported clinical research
Ramzi Abboud, M.D.
Washington University School of Medicine
4 years of reported clinical research
Puja Kachroo, MD
Washington University/Barnes Jewish Hospital
7 years of reported clinical research
Clinical Trials running at Barnes Jewish Hospital
Breast Cancer
Stroke
Multiple Myeloma
Atrial Fibrillation
Relapse
Atrial Flutter
Cardiovascular Disease
Heart Disease
Aortic Stenosis
Aortic Aneurysm
PF-07220060 + Letrozole
for Breast Cancer
The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface); * locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastatic disease (the spread of cancer to other places in the body) * who have not received any prior systemic anti-cancer treatment for advanced/metastatic disease. Approximately half of the participants will receive PF-07220060 plus letrozole while the other half of participants will receive the investigator's choice of treatment plus letrozole. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.
Recruiting
2 awards
Phase 3
4 criteria
PF-07248144 + Fulvestrant
for Breast Cancer
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called receptors that bind to hormones like estrogen and progesterone (female sex hormones). These hormones can promote the growth of cancer cells. HER2-negative describes cells that have a small amount or none of a protein called HER2 on their surface. In normal cells, HER2 helps control cell growth. Cancer cells that are HER2-negative may grow more slowly and are less likely to recur (come back) or spread to other parts of the body than cancer cells that have a large amount of HER2 on their surface. Advanced cancer is a term that is often used to describe cancer that is unlikely to be cured. Metastatic cancer is the type where the cancer cells spread from one part of the body to another. This study is seeking for participants whose breast cancer has gotten worsen after receiving cyclin dependent kinase (CDK) 4/6 inhibitor-based therapy. Half of participants in this study will receive their usual study treatment, everolimus with endocrine therapy (either exemestane or fulvestrant) for HR-positive/HER2-negative advanced or metastatic breast cancer (A/mBC). The study doctor will discuss which hormone therapy is right for the participant before treatment begins. PF-07248144 is a tablet that will be taken by mouth at home every day in a 28-day cycle. Fulvestrant will be given as two injections (one injection in the buttock) at visits to the study clinic. Everolimus and exemestane are also tablets and will be taken by mouth at home every day in a 28-day cycle. The study will compare the experiences of people receiving PF-07248144 in combination with fulvestrant to those of the people who do not. This will help see if PF-07248144 in combination with fulvestrant is safe and effective.
Recruiting
2 awards
Phase 3
4 criteria
Disitamab Vedotin + Tucatinib
for Breast Cancer
This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are few treatment options for patients with advanced or metastatic solid tumors that express HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). Disitamab vedotin is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial uses a drug called tucatinib, which has been approved to treat cancer in the United States and some other countries. This drug is sold under the brand name TUKYSA®. This study will test how safe and how well DV with tucatinib works for participants with solid tumors. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.
Recruiting
1 award
Phase 2
6 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Barnes Jewish Hospital?
Barnes Jewish Hospital is a medical facility located in Saint Louis, Missouri. This center is recognized for care of Lung Cancer, Breast Cancer, Lymphoma, Heart Failure, Leukemia and other specialties. Barnes Jewish Hospital is involved with conducting 384 clinical trials across 607 conditions. There are 35 research doctors associated with this hospital, such as Yan Wang, David G Mutch, M.D., Ramzi Abboud, M.D., and Puja Kachroo, MD.
Where is Barnes Jewish Hospital located?
Barnes-Jewish Hospital is situated on the Washington University Medical Campus in the Central West End neighborhood of St. Louis, Missouri, just one block north of the I-64/US40 and Kingshighway Boulevard intersection. The hospital offers easy access from various locations in the St. Louis area, featuring multiple entrances and parking options.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Barnes Jewish Hospital: - Contact a social worker at (314) 362-5574 or (314) 747-1236 for the main campus. - For insurance inquiries, call (314) 362-8400. - To apply for free or discounted care, fill out the Financial Assistance Application form within 240 days following the date of service and submit it by mail, email, or fax. - For general information or physician referral, call (314) 747-3000 or (888) 998-7953.
What insurance does Barnes Jewish Hospital accept?
Barnes Jewish Hospital accepts a wide range of insurance plans, such as Anthem Blue Cross and Blue Shield, Healthcare USA, AARP, HealthLink, Blue Cross and Blue Shield of Missouri, and HFN, Inc. It is also accessible through Aetna CVS Health in specific counties and Blue Cross Blue Shield of Illinois in most Illinois counties. Always verify eligibility and coverage details with your insurance carrier, as plans may vary.
What awards or recognition has Barnes Jewish Hospital received?
Barnes Jewish Hospital in Saint Louis, Missouri, is recognized for its Magnet designated nursing program, emphasizing quality research and evidence-based practice. It offers a 30-week Evidence-Based Practice Fellowship Program for nursing and allied health professionals. The hospital is consistently ranked among the nation's top hospitals by U.S. News & World Report and has received an "exceptional" rating for its Alvin J. Siteman Cancer Center from the National Cancer Institute.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.